Atlas Trials

Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

Clinical trial NCT04631601 · TERMINATED

Trial details

NCT number
NCT04631601
Sponsor
Amgen
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Metastatic Castration-resistant Prostate Cancer
Start date
2021-01-15
Primary completion
2023-10-23
Enrollment
65

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.